Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Focal Segmental Glomerulosclerosis”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Early research (Phase 1)Study completedNCT05314231
What this trial is testing

Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

Who this might be right for
Proteinuria
Alexion Pharmaceuticals, Inc. 13
Testing effectiveness (Phase 2)Ended earlyNCT05441826
What this trial is testing

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Tenet Medicines 1
Early research (Phase 1)Study completedNCT00193648
What this trial is testing

Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Glomerulosclerosis
Northwell Health 21
Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing

Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84
Post-approval studies (Phase 4)Study completedNCT02633046
What this trial is testing

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Who this might be right for
Idiopathic Focal Segmental Glomerulosclerosis
Mallinckrodt ARD LLC 63
Early research (Phase 1)Ended earlyNCT00816478
What this trial is testing

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Who this might be right for
Focal Segmental Glomerulosclerosis
Northwell Health 15
Testing effectiveness (Phase 2)Study completedNCT01573533
What this trial is testing

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 9
Not applicableLooking for participantsNCT04065438
What this trial is testing

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Testing effectiveness (Phase 2)Study completedNCT02921789
What this trial is testing

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Who this might be right for
Kidney TransplantationPrimary Focal Segmental Glomerulosclerosis (FSGS)
Astellas Pharma Global Development, Inc. 67
Not applicableStudy completedNCT07702981
What this trial is testing

Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

Who this might be right for
Membranous NephropathyMinimal Change Disease (MCD)Focal Segmental Glomerulosclerosis (FSGS)
University Hospital, Ioannina 40
Testing effectiveness (Phase 2)Study completedNCT04983888
What this trial is testing

Obinutuzumab in Primary FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 20
Testing effectiveness (Phase 2)Study completedNCT00814255
What this trial is testing

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Who this might be right for
Focal Segmental Glomerulosclerosis
NYU Langone Health 32
Post-approval studies (Phase 4)Study completedNCT01155141
What this trial is testing

Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH

Who this might be right for
Kidney Diseases
Stanford University 15
Early research (Phase 1)Study completedNCT00464321
What this trial is testing

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Who this might be right for
Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)Study completedNCT05267262
What this trial is testing

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Who this might be right for
Alport SyndromeFocal Segmental Glomerulosclerosis
River 3 Renal Corp. 43
Not applicableStudy completedNCT04369183
What this trial is testing

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change Disease
Istanbul University 25
Large-scale testing (Phase 3)Looking for participantsNCT07220083
What this trial is testing

Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim 286
Testing effectiveness (Phase 2)Study completedNCT02000440
What this trial is testing

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Glomerulosclerosis, Focal Segmental
GlaxoSmithKline 17
Testing effectiveness (Phase 2)Study completedNCT03649152
What this trial is testing

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

Who this might be right for
Focal Segmental Glomerulosclerosis
Dimerix Bioscience Pty Ltd 8
Early research (Phase 1)WithdrawnNCT00816504
What this trial is testing

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Who this might be right for
Focal Segmental Glomerulosclerosis
Northwell Health
Next Page